![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Masserano, L Gong, H Kulaga, I Baker and RJ Wyatt
National Institute of Mental Health Neuroscience Center at Saint Elizabeths, Neuropsychiatry Branch, Washington, D.C. 20032, USA. masseraj@dirpc.nimh.nih.gov
Dopamine produces a time- and dose-dependent increase in cell death in a clonal catecholaminergic cell line (CATH.a) derived from the central nervous system. Cell death also occurred after treatment with the catecholamines L-dihydroxyphenylalanine, norepinephrine, epinephrine, and isoproterenol, as well as the neurotoxic compound 6- hydroxydopamine. Cell death is not receptor mediated because selective noradrenergic and dopaminergic receptor agonists had no effect on CATH.a cell viability. Dopamine induces apoptotic cell death as indicated by DNA fragmentation measured by gel electrophoresis and by flow cytometric analysis. Apoptosis seems to be produced by dopamine autoxidation, because intracellular peroxides increase after dopamine treatment and cell death can be inhibited by catalase and N- acetylcysteine. N-acetylcysteine produced a dose-dependent decrease in dopamine-induced cell death; this correlated with a decrease in peroxide formation. In addition, antisense to the antioxidant protein bcl-2 increases the sensitivity of CATH.a cells to dopamine-induced cell death. These findings indicate that the oxidative products of dopamine cause neurotoxicity through apoptosis.
This article has been cited by other articles:
|
|
 |
|
  M. Quik, L. Chen, N. Parameswaran, X. Xie, J. W. Langston, and S. E. McCallum Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci., April 26, 2006; 26(17): 4681 - 4689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eisenhofer, I. J. Kopin, and D. S. Goldstein Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine Pharmacol. Rev., September 1, 2004; 56(3): 331 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang and G. S. Oxford Voltage-Dependent Ion Channels in CAD Cells: A Catecholaminergic Neuronal Line That Exhibits Inducible Differentiation J Neurophysiol, December 1, 2000; 84(6): 2888 - 2895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Srivastava, S. J. Sollott, L. Khan, R. Hansford, E. G. Lakatta, and D. L. Longo Bcl-2 and Bcl-XL Block Thapsigargin-Induced Nitric Oxide Generation, c-Jun NH2-Terminal Kinase Activity, and Apoptosis Mol. Cell. Biol., August 1, 1999; 19(8): 5659 - 5674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Luo, H. Umegaki, X. Wang, R. Abe, and G. S. Roth Dopamine Induces Apoptosis through an Oxidation-involved SAPK/JNK Activation Pathway J. Biol. Chem., February 6, 1998; 273(6): 3756 - 3764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Daily, A. Vlamis-Gardikas, D. Offen, L. Mittelman, E. Melamed, A. Holmgren, and A. Barzilai Glutaredoxin Protects Cerebellar Granule Neurons from Dopamine-induced Apoptosis by Dual Activation of the Ras-Phosphoinositide 3-Kinase and Jun N-terminal Kinase Pathways J. Biol. Chem., June 8, 2001; 276(24): 21618 - 21626. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
